← Back to All US Stocks

ACH Stock Analysis - ACCENDRA HEALTH INC/VA/ AI Rating

ACH NYSE Wholesale-Medical, Dental & Hospital Equipment & Supplies VA CIK: 0000075252
Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31
AI Rating
STRONG SELL
95% Confidence

Investment Thesis

Accendra Health demonstrates severe financial distress with negative stockholders' equity of -$461M, indicating liabilities exceed assets and shareholders have lost their stake. The company is burning cash with -$360.9M free cash flow while generating substantial operating losses (-$1.1B net income), coupled with deteriorating liquidity ratios that signal imminent solvency risk.

ACH Strengths

  • + Revenue growth of 3.1% YoY indicates modest market demand despite financial struggles
  • + Reasonable gross margin of 19% demonstrates some pricing power at the product level
  • + Cash position of $282M provides temporary buffer for operational needs

ACH Risks

  • ! Negative stockholders' equity of -$461M represents technical insolvency and shareholder equity destruction
  • ! Negative free cash flow of -$360.9M with net loss of -$1.1B indicates unsustainable business model
  • ! Critical liquidity crisis with current ratio of 0.58x and quick ratio of 0.50x - unable to cover short-term obligations
  • ! Long-term debt of $1.8B against negative equity creates structural bankruptcy risk
  • ! Interest coverage of 0.3x means operating income cannot service debt obligations
  • ! Negative operating cash flow of -$170M despite positive revenue indicates operational dysfunction

Key Metrics to Watch

ACH Financial Metrics

Revenue
$2.8B
Net Income
$-1.1B
EPS (Diluted)
$-14.31
Free Cash Flow
$-360.9M
Total Assets
$2.5B
Cash Position
$282.0M

ACH Profitability Ratios

Gross Margin 19.0%
Operating Margin 1.0%
Net Margin -39.8%
ROE N/A
ROA -44.9%
FCF Margin -13.1%

ACH Balance Sheet & Liquidity

Current Ratio
0.58x
Quick Ratio
0.50x
Debt/Equity
N/A
Debt/Assets
118.8%
Interest Coverage
0.26x
Long-term Debt
$1.8B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI